Find Academic Supervisors

• Bioelectronics
• Nanotechnology
• CMOS Technology
• +12 more

Sandro Carrara is a Full Professor at École Polytechnique Fédérale de Lausanne (EPFL), where he leads the Bio/CMOS Interfaces (BCI) laboratory. He is affiliated with the School of Engineering (STI), the Institute of Electrical Engineering (SCI-STI-SC), and the Integrated Systems Laboratory (LSI). His academic leadership spans teaching, doctoral supervision, and editorial roles in major journals including IEEE Sensors Journal and BioNanoScience. Education: Diploma in Electronics, National Technical Institute of Albenga, Italy Master in Physics, University of Genoa, Italy PhD in Biochemistry and Biophysics, University of Padua, Italy His research focuses on the integration of biological systems with CMOS technology, particularly in the development of nanoscale biosensors for health monitoring. Key areas include memristive biosensors, wearable and implantable sensors, electrochemical detection, and therapeutic drug monitoring. His work bridges electronics, nanotechnology, and biomedicine to enable point-of-care diagnostics and personalized medicine. His recent publications (2023–2025) show a strong trend toward sustainable printed electronics, machine learning for biosensing, in-memory computing for cancer diagnostics, and remote health monitoring. These works appear in high-impact journals such as IEEE Sensors Journal , Nanoscale , and Biosensors and Bioelectronics: X . Scientific Awards: IEEE Fellow (2015) IEEE Sensors Council Technical Achievement Award (2016) Distinguished Lecturer, IEEE Sensors Council (2017) Best Paper Award, IEEE MeMeA Symposium (2020) Multiple Gold and Bronze Leaf Prizes at PRIME and IEEE conferences Best Poster Awards at EMBEC and Nano-Tera meetings He actively advises PhD students and leads research projects involving CMOS-based biosensors, wireless implants, and smart sensor systems. His lab collaborates widely across disciplines and institutions, focusing on real-world applications in oncology, neurology, and environmental health. He has also contributed to the development of battery-free wearable devices, optical power transfer systems, and IoT-enabled telemedicine platforms. Laboratories and Teams: Bio/CMOS Interfaces (BCI) Laboratory, EPFL Integrated Systems Laboratory (LSI), EPFL Collaborations with IEEE Sensors Council and Circuits and Systems Society Editorial leadership in IEEE Sensors Journal and BioNanoScience

• Natural Products Research
• Phytomedicine
• Herbal Product Standardization
• +7 more

Roles & Affiliations: Ikhlas Khan serves as Director of the National Center for Natural Products Research (NCNPR), Distinguished Professor, and Research Professor of Pharmacognosy at the University of Mississippi's School of Pharmacy. He also leads the FDA Program and coordinates natural products research across multiple initiatives, including the Sino-US TCM Research Center and the Center for Research of Indian Systems of Medicine (CRISM). Education: B.Sc. Chemistry (1980) - Aligarh Muslim University, India M.Sc. Organic Chemistry (1982) - Aligarh Muslim University, India Ph.D. Pharmacy (1987) - Ludwig-Maximilians-Universität, Munich Postdoctoral Studies - Swiss Federal Institute of Technology (ETH), Zurich Research Focus: Dr. Khan specializes in natural products research with emphasis on: Phytomedicine: Standardization of herbal products via analytical fingerprinting, pesticide/herbicide residue analysis, and bioanalytical quality control. Drug Discovery: Isolation of bioactive natural products, development of analytical methods for phytochemical characterization, and chiral separation techniques. Metabolism Studies: Role of metabolism in drug/natural product activity, particularly in aminoquinoline antimalarials. His work bridges academia, industry, and regulatory bodies, shaping policies for botanical supplements. Key Contributions: Over 850 peer-reviewed publications and leadership in high-impact projects like the FDA Center of Excellence. His lab pioneered methods to combat herbal product adulteration and safety issues. Awards & Recognition: UM Distinguished Professor Award (2018) Wiley Award (AOAC International, 2018) Qihuang International Prize (2017) Honoris Causa Doctorate (University of Hamdard, 2012) Labs & Collaborations: Directs the NCNPR, a global leader in natural products research, and collaborates with institutions worldwide. His team develops technologies for herbal product authentication and drug metabolism studies.

Hai-Quan MaoView profile

Professor

• Biomaterials
• Regenerative Engineering
• Therapeutic Delivery
• +3 more

Hai-Quan Mao is a Professor of Materials Science and Engineering at Johns Hopkins University, with a joint appointment in the Biomedical Engineering Department (School of Medicine). He directs the Institute for NanoBioTechnology (INBT) and leads the Translational Tissue Engineering Center. His research focuses on biomaterials, regenerative engineering, and immunoengineering, particularly developing nanomaterials for therapeutic delivery and tissue regeneration. Mao holds 35 U.S. patents, co-founded two biotech companies, and received prestigious awards including National Academy of Inventors Fellow and NSF CAREER Award. Education: BS in Chemistry (1988) and PhD in Polymer Chemistry (1993) from Wuhan University. Postdoctoral training at Johns Hopkins (1995–1998), followed by roles at Johns Hopkins Singapore (1999–2003) before joining the Whiting School faculty. Research emphasizes nanofiber scaffolds for liver/nerve regeneration, DNA/lipid nanoparticle engineering for gene therapy, and artificial lymph node matrices for immunotherapy. His lab translates biomaterials innovations into clinical applications, with NIH-funded projects addressing cancer, malaria, and tissue damage. Awards include over 60 provisional patents, multiple Johns Hopkins translational awards, and Thalheimer Awards for research. He serves as associate editor of Biomaterials and editorial board member of major journals. Lab activities include scalable nanoparticle manufacturing, machine learning for material design, and collaborations with industry/clinical partners. Recent work includes lipid nanoparticle optimization for mRNA vaccines and exosome-based therapies for Crohn’s disease.

• Drug Delivery
• Nanomedicine
• Biopharmaceutics
• +7 more

Dr. Shyh-Dar Li is a Professor and Tong Louie Chair in Pharmaceutical Sciences at the University of British Columbia's Faculty of Pharmaceutical Sciences, where he also serves as Chair of Nanomedicine and Chemical Biology. With a BSc in pharmacy from National Taiwan University (1998) and PhD in pharmaceutical sciences from UNC Chapel Hill (2008), followed by postdoctoral training at UC San Diego's Moores Cancer Center (2009), Dr. Li has established himself as a leading researcher in advanced drug delivery systems. His research focuses on developing innovative nanomedicine platforms for targeted delivery of biological therapeutics including peptides, proteins, antibodies, and nucleic acids. Dr. Li's laboratory has pioneered several novel drug delivery approaches, particularly in lipid-based nanoparticles, phospholipid-free vesicles, and polymer systems for cancer immunotherapy, pain management, and protein delivery. His work bridges fundamental nanotechnology with translational applications for difficult-to-treat diseases. Analysis of his recent publications reveals a strong emphasis on tumor microenvironment modulation, endosomal escape mechanisms for nucleic acid delivery, and non-invasive delivery routes for protein therapeutics. His research demonstrates increasing sophistication in nanocarrier engineering, with recent work incorporating machine learning approaches to optimize nanoparticle design and expanding into immunomodulatory therapies that harness the body's immune system to fight cancer. Scientific Recognition: 2014 AFPC New Investigator Award 2013 AAPS New Investigator Award in Pharmaceutics and Pharmaceutical Technologies 2013 CIHR New Investigator Award 2013 CSPS Early Career Award 2012 Prostate Cancer Foundation Young Investigator Award Dr. Li's research program has been consistently supported by major Canadian funding agencies including CIHR, NSERC, and MITACS. He actively collaborates across disciplines and accepts graduate students into his research program, focusing on cutting-edge approaches to overcome biological barriers in drug delivery. His laboratory, the Laboratory of Targeted Drug Delivery and Nanomedicine, serves as a hub for innovation in pharmaceutical nanotechnology.

Michael McAlpineView profile

Professor

• 3D Printing
• Nanotechnology
• Biomedical Engineering
• +4 more

Michael McAlpine is a Professor in the Mechanical Engineering department at the University of Minnesota . He also holds affiliations with the Biomedical Engineering and Electrical and Computer Engineering departments. His research focuses on 3D printing functional materials & devices , Nanoscale inks , Biomedical devices , Bioelectronics , and Flexible Microsystems . Research Interests : 3D Printing, Biomedical Engineering, Nanotechnology, Flexible Electronics, Microfluidics Labs : ME 361/363 Contact : mcalpine@umn.edu , (612) 626-3303, ME 117 Recent Research Trends include 3D Printed Biomedical Devices , Flexible Electronics , and Bioprinting Applications . His work spans from Spinal Organoid Formation to Programmable Drug Release Capsules . Scientific Award : Circulation Research 2020 Best Manuscript Award

Ahmet AcarView profile

Associate Professor

• Cancer Biology
• Precision Medicine
• Drug Resistance Mechanisms
• +3 more

Dr. Ahmet Acar is an Associate Professor at the Department of Biological Sciences, Middle East Technical University (METU), Ankara, Turkey. He leads the Cancer Precision Medicine and Drug Resistance Laboratory, focusing on understanding mechanisms of drug resistance in cancer. His research integrates experimental models, next-generation sequencing, and deep learning to address clinical challenges in cancer therapy. Dr. Acar holds a B.Sc. from METU's Biological Sciences department and a Ph.D. from the Cancer Research UK Manchester Institute. He completed postdoctoral training at the Institute of Cancer Research, London, and the University of Manchester. Research Interests: Drug resistance mechanisms, precision oncology, tumor microenvironment modeling, patient-derived organoids, computational pathology, and evolutionary cancer biology. His lab develops 2D/3D co-culture systems, PDO biobanks, and AI-driven histopathology tools to improve treatment strategies. Recent Work Trends: Recent publications emphasize tumor evolution modeling, matrix mechanics in drug resistance, and AI applications in histopathology. Collaborations with hospitals in Turkey and Europe support PDO biobank initiatives. His team explores evolutionary steering strategies to exploit collateral drug sensitivities. Labs/Teams: Precision Medicine and Drug Resistance Lab at METU focuses on interdisciplinary approaches combining wet-lab experiments with computational methods. Current projects include ex vivo tumor modeling and AI-driven diagnostic tools for oncology.

Kelly ArnoldView profile

Associate Professor

• Biomedical Computation and Modeling
• Drug Delivery and Therapeutics
• Systems Immunology
• +5 more

Kelly Arnold is an Associate Professor in the Department of Biomedical Engineering at the University of Michigan. Her research integrates systems engineering principles with immunology to investigate variability in immune responses across infection, vaccination, and injury, with a focus on computational modeling and clinical translation. Research Focus Systems-level immune response modeling Vaccination and antibody functionality Vaginal microbiome-host interactions Chronic lung disease progression Computational serology and proteomics Recent Work Her 2025 studies examine SARS-CoV-2 vaccination responses in cancer patients and computational frameworks for vaginal probiotics. Earlier works (2024-2007) span COPD progression, lupus fibrosis, HIV susceptibility, and tissue engineering for fertility preservation. Methodologies include proteomic profiling, network modeling, and microfluidic systems.

• Nanomedicine
• Therapeutic Targeting
• Drug Delivery Systems
• +4 more

Dr. Susan Hua is an Associate Professor at the University of Newcastle's School of Biomedical Sciences and Pharmacy, specializing in translational nanopharmaceutics and therapeutic targeting. She established the first translational nanopharmaceutics laboratory in the Hunter region, focusing on drug delivery systems for gastrointestinal, musculoskeletal, and reproductive pathologies. Education: Bachelor of Pharmacy with Honours, University of Queensland (UQ) PhD in Neuroscience and Nanotechnology, UQ Research Interests: Her work centers on using nanotechnology to create targeted drug delivery systems for diseases such as chronic pain, inflammatory conditions, and obstetric complications. Key focuses include oxytocin receptor-targeted liposomes for uterine therapies and localized drug delivery to bypass biological barriers. Awards & Recognition: 2020 DVC(A) Educator Innovation Award 2017 NSW Premier's Early Career Researcher of the Year 2015 HMRI Early Career Researcher of the Year Grants & Collaborations: A/Prof Hua has secured over $5.5M in grants, including NHMRC and ARC funding. She collaborates with institutions like HMRI, John Hunter Hospital, and global teams on projects like nanoparticle-based treatments for preterm labor and uterine hemorrhage. Teaching & Leadership: She coordinates pharmacy programs, emphasizing clinical application and innovation. Her courses include Pharmacotherapeutics and Pharmacy Practice, with awards for teaching excellence (2020, 2011). Labs & Programs: Head of Therapeutic Targeting Program, University of Newcastle Director, Translational Pharmaceutics & Medical Technologies Theme (HMRI)

Waldemar KolanusView profile

Professor

• Molecular Immunology
• Cell Signaling
• Signal Transduction Pathways
• +4 more

Prof. Waldemar Kolanus leads the Molecular Immunology and Cell Biology department at the University of Bonn's Life & Medical Sciences Institute (LIMES) . His research bridges immunoregulation , stem cell dynamics , and metabolic stress responses in immune cells. Unit 2 member at LIMES Principal investigator in SFB 704 and ImmunoSensation Cluster Leads a multidisciplinary lab with postdocs, PhD students, and technical staff His work focuses on intracellular signaling pathways connecting immune activation to tissue homeostasis, particularly through: Cytohesin proteins in integrin-mediated adhesion and migration TRIM71 in stem cell regulation and congenital hydrocephalus High-salt environments affecting macrophage function Publication trends show expertise in immune cell migration , genetic models , and chemical inhibition , with frequent use of mice and zebrafish for in vivo studies. Key articles explore: TRIM71's dual role in auditory development and germ cell maintenance Cytohesin family's Golgi regulation and insulin signaling Ruxolitinib's off-target migration inhibition of dendritic cells Contact details: Address: LIMES Institute, Carl-Troll-Straße 31, Bonn Email: kolanus.sekretariat@uni-bonn.de Phone: +49 228 73-62788

• Stem Cell Mechanobiology
• Bone Tissue Engineering
• Regenerative Medicine
• +3 more

Chao Liu is an Associate Professor at the Department of Biomedical Engineering , Southern University of Science and Technology (2024.11–present). Previously, he served as an Assistant Professor at the same institution (2019–2024.11) and completed a Postdoctoral Fellowship at New York University (2016–2019) with joint appointments in the Department of Biomedical Engineering and Orthopedics at NYU Langone Health . He holds a PhD in Biomedical Engineering (2016) and MASc in Mechanical Engineering (2010) from University of Toronto , following a BASc in Engineering Science (2008). Education : PhD (IBBME, U of Toronto, 2016), MASc (Mechanical Engineering, U of Toronto, 2010), BASc (Engineering Science, U of Toronto, 2008) His research focuses on mechanobiology of stem cells , bone tissue engineering , and functional implants . He investigates how mechanical forces modulate osteogenic and angiogenic stem cells, designs implants with micro-geometry to enhance cellular activity, and develops 3D real-time imaging modalities for bone repair processes. His work spans biomechanics , regenerative medicine , and cellular mechanotransduction . The selected publications from 2022 to 2010 reveal trends in mechanical force applications for bone regeneration, pharmacological impairments in healing, nanostructured biomaterials for stem cell differentiation, and microfluidic platforms for osteocyte studies. These works are published in journals like Bone , FASEB Journal , and ACS Applied Materials & Interfaces . Scientific Awards : International Conference BME Young Investigator Award (2019), IFMRS Travel Grant (2017), ASBMR Young Investigator Grant (2016), CIHR Travel Awards (2010–2014), Ontario Graduate Scholarship (2011–2013), Barbara and Frank Milligan Fellowship (2008, 2010) Chao Liu mentors graduate students, including Zhang Jianing (2022 Master’s graduate). His lab ( https://abtrl.bme.sustech.edu.cn/ ) recruits postdocs and research assistants for projects in mechanical force applications , micro-geometric implants , and 3D imaging . He has contributed to 14 journal articles with 714 citations and presented at 6 international conferences in the past three years.

• Dynamics of Innovation
• Regulatory Sciences
• Economics of Science and Innovation
• +5 more

Dr. Jarno Hoekman is an Associate Professor in Innovation Studies at the Copernicus Institute of Sustainable Development, Utrecht University. His research focuses on the dynamics and governance of science in the context of innovation, regulation, and societal challenges, with particular emphasis on sustainability and health. He is affiliated with both the Copernicus Institute of Sustainable Development and the Utrecht collaborating Centre for Pharmaceutical Policy & Regulation in the Department of Pharmaceutical Sciences. Dr. Hoekman serves as the programme leader of the research master in Innovation Sciences and teaches academic integrity courses to Master students and PhD candidates. Dr. Hoekman's research is organized around three interconnected themes: Science in transition , examining how scientific practices and institutional arrangements are evolving through open science, interdisciplinary research collaborations, and alternative recognition systems; Regulatory science and innovation , investigating innovations in tools and standards for assessing risks and benefits of new technologies, including safety assessment methods and regulatory authorization standards; and Geography of science , exploring the role of location factors in scientific knowledge production and diffusion. Analysis of Dr. Hoekman's recent publications (2022-2024) reveals a strong interdisciplinary focus spanning pharmacology, toxicology, innovation studies, and science policy. Key research trends include examining conditional marketing authorization pathways, post-approval studies for conditionally authorized medicines, animal-free safety testing methodologies, and the societal impact of transdisciplinary research projects. His work frequently employs mixed-methods approaches and involves multi-stakeholder perspectives to address complex regulatory and innovation challenges. Dr. Hoekman actively contributes to policy-relevant research, including major European Commission studies on pharmaceutical legislation. His collaborative work extends across multiple institutions and involves interdisciplinary teams working on pharmaceutical policy, sustainable innovation, and science-society interactions. As a member of the Utrecht Young Academy and the UU Open Science Platform, he engages with broader academic community initiatives related to research integrity and open science practices.

• Biostatistics
• Genetics
• Maternal & Child Health
• +4 more

Heping Zhang is the Susan Dwight Bliss Professor of Biostatistics at the Yale School of Public Health , with secondary appointments in the Child Study Center , Department of Statistics and Data Science , and Department of Obstetrics, Gynecology, and Reproductive Sciences . He directs the Collaborative Center for Statistics in Science (C²S²) and leads the Reproductive Medicine Network data coordinating center. Education: PhD in Statistics, Stanford University (1991) Postdoctoral Fellow, Mathematical Science Research Institute (1991) Research Focus : Zhang specializes in biostatistical methodology for genomic data analysis , clinical trials , and reproductive medicine . His work bridges genetics , mental health , and maternal-child health through innovative statistical approaches. Awards : 2023 Web of Science Highly Cited Researcher 2023 International Chinese Statistical Association Distinguished Achievement Award 2022 Institute of Mathematical Statistics Neyman Award and Lecture 2011 Royan Institute International Research Award 2011 Institute of Mathematical Statistics Medallion Award 2008 Harvard School of Public Health Myrto Lefokopoulou Distinguished Lecturer Professional Roles : He served as President of the International Chinese Statistical Association (2019) and Former Editor of the Journal of the American Statistical Association - Applications and Case Studies . His lab develops open-source software tools like ABESS , STREE , and modSaRa for genomic and clinical data analysis.

• Radiation Biology
• Radiation Carcinogenesis
• Radiation Applications in Medicine
• +3 more

John Ford is an Associate Professor in the Department of Nuclear Engineering at Texas A&M University. His research focuses on radiobiology, radiation carcinogenesis, and medical applications of radiation. He holds academic appointments within the College of Engineering and contributes to the Health Physics, Radiation Biology & Medical Physics research group. Education includes a B.S. and M.S. in Nuclear Engineering from Mississippi State University (1982, 1986), a Ph.D. in Biomedical Sciences from the University of Tennessee (1992), and postdoctoral training at Oak Ridge National Laboratory (1992–1993). His work emphasizes understanding radiation effects on biological systems, with notable contributions to radiation dosimetry, bystander signaling mechanisms, and dietary modulation of radiation damage. Recent studies explore space radiation monitoring technologies and therapeutic applications of radiation. Awards include the BP Award for Teaching Excellence (2007) and ARRO Educator of the Year (2013–2014). Research spans interdisciplinary areas such as radiation-induced cancer mechanisms, nutritional interventions to mitigate radiation effects, and advanced radiation detection instrumentation. He has advised numerous projects in radiation safety curriculum development and collaborated on NASA-funded studies modeling radiation impacts on astronauts.

• Biomaterials
• Tissue Engineering
• Regenerative Medicine
• +12 more

Professor Hala Zreiqat AM is a leading biomedical engineer at The University of Sydney , serving as the Director of the ARC Training Centre for Innovative BioEngineering . A Fellow of all major Australian academies (AAS, ATSE, FAHMS, FRSN), she develops 3D printed bioceramics for bone regeneration while championing diversity through initiatives like the IDEAL Society and BIOTech Futures mentorship program. Her work bridges academia, clinical practice, and industry in musculoskeletal research . Research Focus: Her lab creates synthetic bone scaffolds that mimic natural bone architecture, strength, and porosity, enabling non-rejected bone regeneration via patient-matched implants. Key applications include orthopaedic, dental, and maxillofacial repair , with over $18M in competitive funding and multiple patents. Current projects explore AI-driven scaffold performance prediction and anti-senescence strategies for aging-related bone loss. Scientific Trends: Recent publications highlight 3D printed nanovoxelated ceramics , antisenescence biomaterials , and multifunctional theranostic platforms . Her team integrates machine learning for scaffold design, atom probe tomography for interface analysis, and two-photon imaging for cellular monitoring in 3D environments. 2021-2022 Fulbright Senior Scholar 2018 NSW Premier's Woman of the Year 2019 Eureka Prize for Innovative Use of Technology Fellow of Australian Academy of Science (2021) Over $18M in research funding Teaching & Leadership: She designed core courses like Tissue Engineering and Nanomaterials in Medicine , mentoring 158 students in 2020 alone. As Chair of CAAR (2020-2023), she strengthens Australia-Arab collaborations. Her lab trains early-career researchers , with alumni now in academia and industry.

• Stem Cell Biology
• Genetic Engineering
• Epigenetics
• +5 more

Konstantinos Anastassiadis is a Professor at the Center for Molecular and Cellular Bioengineering (CMCB) of Dresden University of Technology , leading the Stem Cell Engineering group at the Biotechnology Center (BIOTEC) . His research focuses on unraveling molecular pathways regulating stem cell self-renewal and lineage commitment, with a strong emphasis on genetic engineering tool development and epigenetic mechanisms during cellular reprogramming. The lab utilizes mouse and human embryonic stem cells, neural stem cells, mesenchymal stromal cells, and induced pluripotent stem cells (iPSCs) in their investigations. Core Research Areas: Molecular regulation of stem cell fate Epigenetic mechanisms (e.g., UTX/UTY histone demethylases) Genetic engineering tool development (Flp, Dre, Vika recombinases, CRISPR protocols) Conditional immortalization systems for rare cell expansion Publications highlight his contributions to understanding: Role of histone methyltransferases (MLL1, MLL2, Setd1b) in hematopoiesis and cancer Epigenetic regulation during mouse development and spermatogenesis Genetic tools for protein tagging, transposon-mediated BAC transgenesis Interactions between stem cells and niche microenvironments Transcriptional and mechanical markers during reprogramming Collaborations span immunology , developmental biology , and bioinformatics . The lab actively participates in teaching activities at CMCB and maintains a focus on translational applications of stem cell research.